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Background: Acute lung injury (ALI) induced by cardiopulmonary bypass (CPB, CPB-ALI) is a common and serious
complication after cardiac surgery. And infants and young children are more prone to CPB-ALI. The purpose of this
study was to investigate the perioperative changes of plasma gelsolin (pGSN) in patients below 3years of age with
cardiac surgeries and CPB, and determine whether pGSN are associated with the occurrence and severity of
CPB-ALI.
Methods: Seventy-seven consecutive patients ≤3 years of age with congenital heart diseases (CHD) performed on
open heart surgery with CPB were finally enrolled, and assigned to ALI and non-ALI groups according to the
American-European Consensus Criteria. Plasma concentrations of gelsolin and total protein were measured at
following 8 time points: before CPB (a), after CPB (b), 2 hours after CPB (c), 6 hours after CPB (d), 12 hours after
CPB (e), 24 hours after CPB (f), 48 hours after CPB (g) and 72 hours after CPB (h).
Results: Twenty-seven (35.1%) patients developed CPB-ALI in the study, including eleven (14.3%) patients with
ARDS. The earliest significant drop of pGSN and normalized pGSN (pGSNN) of ALI group both occurred at 6 hours
after CPB (p = 0.04 and p < 0.01), which was much earlier than those of non-ALI group (48 hours, p = 0.03 and
24 hours, p < 0.01); PGSN of ALI group before CPB and 6 hours after CPB were both significantly lower than those
of non-ALI group (p < 0.01); PGSNN of ALI group before CPB and 6 hours after CPB were both significantly lower
than those of non-ALI group (p < 0.01, p = 0.04); PGSN before CPB was the only independent risk factor predicting
the occurrence of CPB-ALI (OR, 1.023; 95% CI, 1.007-1.039; p < 0.01) with an AUC of 0.753 (95% CI, 0.626-0.880); The
optimal cutoff value of pGSN before CPB was 264.2 mg/L, with a sensitivity of 58.3% and a specificity 94.7%. And
lower pGSN before CPB was significantly associated with the severity of CS-AKI (r = −0.45, p < 0.01).
Conclusions: Patients developing CPB-ALI had lower plasma gelsolin reservoir and a much more amount and rapid
consumption of plasma gelsolin early after operation. PGSN before CPB was an early and sensitive predictor of
CPB-ALI in infants and young children undergoing cardiac surgery, and was negatively correlated with the
severity of CPB-ALI.
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Acute lung injury induced by cardiopulmonary bypass, a
common and serious complication in patients undergoing
cardiac surgery necessitating CPB, may impair both lung
mechanics and gas exchange, and becomes an important
factor of morbidity and mortality after surgery [1,2]. 2% of
those patients may develop into acute respiratory distress
syndrome (ARDS) resulting in a mortality of 15% to
50% [3]. Infants and children are more prone to CPB-ALI
which is associated with postoperative pulmonary compli-
cations, prolonged mechanical ventilation, as well as
longer ICU time and hospital resource utilization [4,5].
Therefore, there is increasing interest in developing some
effective biomarkers for prediction of CPB-induced ALI in
infants and children, which would be helpful for early
diagnosis and decision-making.
Gelsolin, a protein of 82-84KDa, is the founding member
of gelsolin protein superfamily, as a cytoplasmic as well as a
plasma isoform, can bind, sever and cap actin filaments.
Plasma gelsolin, primarily secreted by myocytes, is believed
to function as an important actin scavenger in the circula-
tion [6-8]. Besides, emerging data have demonstrated that
pGSN, as an inflammatory mediator-binding protein, also
functions as a lipid carrier with strong binding affinity to
several plasma lipids such as lipopolysaccharide exdotxin,
lipoteichoic acid, lysophosphatidic acid, β-amyloid peptide
and platelet-activating factor, etc., and plays a role in
localizing inflammation and prevent systemic escape of
pro-inflammatory lipids [9-12]. Consistent with these
proposed functions, declining pGSN level has be proved
to be associated with a variety of acute clinical conditions,
such as sepsis, myocardial infarction, major trauma, burn,
allogeneic stem cell transplantation and acute liver
injury, etc. And more importantly, pGSN levels are
inversely related to the clinical outcome under these
conditions [13-18].
For systemic inflammatory response syndrome (SIRS)
is the origin of CPB-ALI, we speculated that pGSN might
play a role in the development of CPB-ALI. The purpose
of this study was to investigate the perioperative changes
of pGSN level in patients below 3 years of age undergoing
cardiac surgeries with CPB, and determine whether pGSN




The study was conducted in a 20-bed Surgical ICU
(SICU) from November 2012 to March 2013 at the chil-
dren’s hospital, Medical College, Zhejiang University, P. R.
China. The present study was approved by local hospital
ethics committee (Medical Ethics Committee, Children’s
Hospital, Medical College, Zhejiang University), and written
informed consents were obtained from their parents.Seventy-seven consecutive patients aged ≤3 years (includ-
ing 3 neonates) with congenital heart diseases undergoing
open heart surgery with CPB were finally enrolled into the
study. Patient with pneumonia, liver/renal dysfunction,
major chromosomal abnormalities, need for mechanical
ventilation before surgery, premature babies, or low
cardiac output syndrome after surgeries was excluded
from the study.
Anesthesia and CPB procedure were managed ac-
cording to the standard protocol. Myocardial protection
was achieved using cold blood cardioplegic solution unless
otherwise indicated. The patients were transferred to
SICU immediately after surgery. Each patient was moni-
tored continuously for hemodynamic and respiratory data.
Blood gas analysis was performed routinely pre-, intra-, and
post-operation. All the patients admitted to SICU were
ventilated with initial inspiratory oxygen fraction
(FiO2) 50% and initial positive end expiratory pressure
(PEEP) 3 cmH2O, and then adjusted to maintain nor-
mocapnia and oxygen saturation (SaO2) higher than
95% with lowest FiO2 and most appropriate PEEP. And
chest radiograph was performed every 24 hours.
The criteria of weaning from invasive ventilation in
our unit are provided in detail in Additional file 1.
Noninvasive ventilation (continuous positive airway
pressure, CPAP) was used immediately after thacheal
extubation in patients at high risk of extubation failure
(EF) (Additional file 1), or started when acute respiratory
failure appears after extubation. The initial CPAP setting
was accorded to the each patient’s age and weight, and
adjusted by the clinical status. Patients not responding
successfully to CPAP were reintubated according to the
criteria provided in Additional file 1, and the decision was
made by the attending physicians.Definition of CPB-ALI
Patients were categorized into CPB-ALI group if they met
the American-European Consensus Criteria within 24 h
after surgery [19]. The diagnosis was made by the physician
blind to the study.Data and blood sampling collection
Whole blood samples (3 ml) were obtained from pa-
tients at following time points: before CPB (a), after CPB
(b), 2 hours after CPB (c), 6 hours after CPB (d), 12 hours
after CPB (e), 24 hours after CPB (f ), 48 hours after CPB
(g) and 72 hours after CPB (h), and were collected in
EDTA-containing tubes. After being centrifuged at 2500 g
for 5 minutes at 4°C, plasma samples were frozen at −80°C
until analysis. PGSN levels were measured using an ELISA
kits (USCN, Wuhan, P. R. China) according to the
manufacturer’s instruction. The plasma total protein
amount (TP) was measured at each time point by an
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USA) for pGSN normalization.
The clinical variables included sex, age, age distribution,
weight, risk adjustment for surgery for congenital heart
disease (RACHS-1), CPB time, aortic cross-clamp time,
nadir HCT (%) during CPB, ultrafiltrated volume removal
(UVR), positive fluid balance after CPB, need for transfu-
sion within 24 hours after CPB, nosocomial pneumonias
(NF), extubation failure (EF), as well as mechanical venti-
lation duration, need for CPAP, ICU stay, hospital stay and
hospital death. The definitions for the clinical variables are
provided in Additional file 2.
Statistical analysis
Continuous variables were tested for normal distribution
by one-sample Kolmogorov-Smirnov test, and were
expressed as mean ± SD if normally distributed, and
otherwise, as median (interquartile range). Student’s t-test
or the Mann–Whitney U-test was used to determine the
significant difference of continuous variables between two
groups; χ2 test was used for the comparison of categorical
variables. The both changes of pGSN and pGSNN (pGSN/
TP ratio, 10−3) level over times of each group were ana-
lyzed by two-way ANOVA, and an analysis of covariance
procedure (ANCOVA) was used to test the differences of
both pGSN and pGSNN between two groups. Logistic re-
gression analysis was used to identify the independent risk
factors for CPB-ALI. The preoperative, intraoperative and
early postoperative variables with a p value less than 0.1
were entered into the logistic model, including age, age
distribution, weight, positive fluid balance after CPB, TP
and pGSN before CPB. Area under the ROC curve was
used to assess how well the factors diagnose CPB-ALI. A
Pearson or Spearman correlation test was performed to
determine the correlation between pGSN and severity of
CS-AKI and other clinical outcomes. A p value less than
0.05 was considered to be statistically significant. Statis-
tical analysis was performed using SPSS 16.0 (SPSS Inc,
Chicago, IL, USA) software version.
Results
Clinical outcomes
During the study period, a total of 77 patients aged ≤ 3 years
were enrolled in the study. Among the 77 patients, 27
(35.1%) developed CPB-ALI, including eleven (14.3%) pa-
tients with ARDS. As shown in Table 1, no differences
were observed in gender distribution, RACHS-1 score,
CPB time, aortic cross-clamp time, nadir HCT during
CPB, UVR, need for transfusion within 24 hours after
CPB, EF or NF incidence and hospital stay between the
two groups. However, compared with patients without
CPB-ALI, the patients with CPB-ALI were significantly
younger in age, especially in patients <1 year of age, lighter
in weight, higher incidence of positive fluid balance afterCPB. In addition, the durations of mechanical ventilation
and ICU stay of ALI group were both longer than those of
non-ALI group; the patients with CPB-ALI were more
likely to require CPAP after thacheal extubation. No pa-
tients died in hospital in this pilot study.
The perioperative changes of plasma gelsolin and
total protein
Plasma gelsolin levels were showed in Table 2, both as
absolute value (pGSN) and normalized value (pGSNN).
For the plasma total protein level after CPB decreased
dramatically (p < 0.01), both pGSN and pGSNN levels
were used for univariate analysis. In the ALI group, both
of the earliest significant drop of pGSN and pGSNN
occurred at 6 hours after CPB compared with those of the
preoperative levels (baseline level, p = 0.04 and p < 0.01),
while the first remarkable drops of pGSN and pGSNN in
non-ALI group occurred at 48 hours after CPB (p = 0.03)
and 24 hours after CPB (p < 0.01) respectively (Figure 1).
The pGSN level of ALI group before CPB and 6 hours
after CPB were (122.6 ± 24.6) mg/L and (89.9 ± 17.6) mg/L,
which were significantly lower than those of non-ALI
group [(176.4 ± 54.5) mg/L, p < 0.01 and (141.0 ± 49.0) mg/L,
p < 0.01]. Likewise, the pGSNN of ALI group before
CPB and 6 hours after CPB were (2.02 ± 0.39) × 10−3
and (1.61 ± 0.26) × 10−3, which were also significantly
lower than those of non-ALI group [(2.77 ± 0.89) × 10−3,
p < 0.01 and (2.18 ± 0.75) × 10−3, p = 0.04] (Table 2,
Figure 2).
The TP level before surgery of ALI group was signifi-
cantly lower than that of non-ALI group [(59.3 ± 5.6)
vs. (64.1 ± 4.8), p < 0.01].
Low plasma gelsolin before CPB as a predictor for CPB-ALI
Logistic regression revealed that pGSN before CPB was the
only independent risk factor for predicting the occurrence
of CPB-ALI (OR, 1.023; 95% CI, 1.007-1.039; p < 0.01)
among the six factors (age, age distribution, weight, positive
fluid balance after CPB, TP and pGSN before CPB). In the
ROC analysis (Figure 3), the AUC of pGSN before CPB
was 0.753 (95% CI, 0.626-0.880). And the optimal cutoff
for pGSN before CPB was 264.2 mg/L, with a sensitivity
of 58.3% and a specificity 94.7%.
Plasma gelsolin predict the severity of CPB-ALI
Lower pGSN before CPB was significantly associated with
the severity of CPB-ALI in this study (Figure 4, r = −0.45,
p < 0.01). Though age, age distribution, weight, positive
fluid balance after CPB and TP before CPB were excluded
from final multiple regression analysis, younger age,
patients ≤1 year of age, lighter weight and low total
protein level before CPB were proved to be significantly
correlated with the severity of CPB-ALI (r = −0.335,
Table 1 Demographic and clinical characteristics of the patients enrolled in the study
Total ALI (n = 27) Non-ALI (n = 50) p
Sex male n (%) 55(71.4) 17(63.0) 38(76.0) 0.27C
Age (months) 9.1 ± 6.8 5.8 ± 4.5 10.9 ± 7.2 0.001a
Age distribution 0.03C
0-1 year old 54 23(42.6) 31(57.4)
1-2 years old 19 4(21.1) 15(78.9)
2-3 years old 4 0(0) 4(100)
Weight (kg) 7.3 ± 2.2 6.0 ± 1.8 8.0 ± 2.1 0.001a
RACHS-1 0.37C
1 10 3 7
2 63 21 42
≥3 4 3 1
CPB time (min) 69.4 ± 23.3 74.6 ± 22.1 66.7 ± 23.7 0.23a
Aortic cross clamp time (min) 50.1 ± 19.6 46.5 ± 17.7 44.2 ± 20.7 0.68a
Nadir HCT during CPB (%) 25.3 ± 2.7 25.2 ± 2.3 25.2 ± 3.0 0.98a
Positive fluid balance after CPB (%) 55(71.4) 24(88.9) 31(62.0) 0.03C
Need for transfusion within 24 hours after CPB (%) 6(7.8) 2(7.4) 4(8.0) 0.93C
Nosocomial pneumonias (%) 15(19.5) 6(22.2) 9(18.0) 0.58C
CPAP (%) 10(13.0) 9(33.3) 4(8.0) 0.04C
EF (%) 3(3.9) 3(11.1) 0(0) 0.12C
MV time (hour) 24(3 ~ 446) 26(4 ~ 446) 6.5(3 ~ 189) 0.001b
SICU stay (day) 5(2 ~ 34) 9.2 ± 6.6 4(2 ~ 34) 0.001b
Hospital stay (day) 23.4 ± 10.0 26.1 ± 11.0 21.9 ± 9.2 0.15a
Hospital death (%) 0 0 0 0.77C
Continuous variables were expressed as the mean ± SD or median (interquartile range) if appropriated. Categorical variable were expressed as number of
patients (%).
a: Student’s t-test; b: Mann–Whitney U-test; C: χ2 test.
RACHS-1 = Risk Adjusted Classification for Congenital Heart Surgery; ALI = acute lung injury; CPB = cardiopulmonary bypass; MV =mechanical ventilation;
CPAP = Continuous positive airway pressure; EF = Extubation failure; SICU = surgery intensive care unit; UVR = ultrafiltered volume removal.
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r = −0.395, p < 0.01).
Discussion
The lungs are proposed to be one of most “sensitive”
organ to the SIRS, especially in pediatric population
[20]. The incidence of CPB-ALI of this cohort was
35.1%, and 14.3% of patients developed ARDS, which was
much higher than that of adult population. In univariate
analysis, we found that weight was much lower in ALI
group, and they were much younger than patients without
ALI. The patients’ weight and age of this study were
significantly correlated with the severity of CPB-ALI
(r = −0.441, p < 0.01; and r = −0.335, p < 0.01). And the
patients below 1 year old were especially prone to
CPB-ALI compared with elder children (42.6% vs. 21.1%),
and was also strongly correlated with the severity of
CPB-ALI (r = −0.383, p < 0.01). Furthermore, we also
demonstrated that the preoperative plasma protein level
of ALI group was much lower than that of non-ALI group(p < 0.01), and patients with ALI were vulnerable to
positive fluid balance after CPB (p = 0.03). So, it seems
that bronchopulmonary immaturity, hypoproteinemia,
additional fluid retention worsens its inability to adapt
the environment of systemic inflammatory response
provoked by CPB, which might consequently aggravate
the increase of permeability, pulmonary vascular resistant
and the changes of lung surfactant, and exacerbate lung
disturbances early after surgery [2,3,21]. Though transfu-
sion of blood products during or after surgery had been
proved to be a strong risk factor of acute lung injury and
might associated with increased mortality in long-term
follow-up [22-24], there were no significant differences of
nadir HCT during CPB and incidence of transfusion early
after surgery between two groups in our study. We pro-
posed that the possible reasons might be the restrictive
transfusion policy both in CPB circuit priming (only in pa-
tients with an estimated nadir HCT ≤25% during CPB)
and after surgery (only in patients with Hb ≤ 7 g/dL or
coagulation dysfuction), and routine use of ultrafiltration
Table 2 Perioperative changes of plasma gelsolin and total protein levels
Total ALI (n = 27) Non-ALI (n = 50) p
Before CPB (a)
TP (g/L) 62.4 ± 5.6 59.3 ± 5.6 64.1 ± 4.8 0.01a
pGSN (mg/L) 157.8 ± 52.8 122.6 ± 24.6 176.4 ± 54.5 0.01a
pGSNN (10
−3) 2.51 ± 0.84 2.02 ± 0.39 2.77 ± 0.89 0.01a
After CPB (b)
TP (g/L) 55.1 ± 4.6 55.3 ± 4.9 55.0 ± 4.7 0.81a
pGSN (mg/L) 138.7 ± 51.9 133.2 ± 54.0 141.7 ± 51.2 0.53a
pGSNN (10
−3) 2.52 ± 0.92 2.41 ± 0.95 2.33 ± 0.98 0.11a
2 hours after CPB (c)
TP (g/L) 56.6 ± 5.2 54.9 ± 4.9 57.5 ± 5.1 0.08a
pGSN (mg/L) 152.0 ± 73.7 142.9 ± 66.9 156.8 ± 77.6 0.65a
pGSNN (10
−3) 2.33(1.26 ~ 0.76) 2.62 ± 1.24 2.747 ± 1.35 0.23a
6 hours after CPB (d)
TP (g/L) 56.9 ± 5.8 55.6 ± 6.6 57.6 ± 4.9 0.22a
pGSN (mg/L) 124.3 ± 47.8 89.9 ± 17.6 141.0 ± 49.0 0.01a
pGSNN (10
−3) 1.80(1.15 ~ 4.63) 1.61 ± 0.26 2.18 ± 0.75 0.04a
12 hours after CPB (e)
TP (g/L) 58.0 ± 4.6 55.7 ± 3.7 59.1 ± 4.7 0.01a
pGSN (mg/L) 135.9 ± 54.0 121.3 ± 38.3 142.5 ± 59.1 0.33a
pGSNN (10
−3) 2.34 ± 0.91 2.19 ± 0.73 2.41 ± 0.98 0.40a
24 hours after CPB (f)
TP (g/L) 58.1 ± 5.4 57.7 ± 4.8 58.3 ± 5.7 0.71a
pGSN (mg/L) 124.6 ± 43.9 133.0 ± 58.2 121.0 ± 36.5 0.37a
pGSNN (10
−3) 2.16 ± 0.75 2.31 ± 0.87 2.09 ± 0.69 0.98a
48 hours after CPB (g)
TP (g/L) 60.1 ± 5.8 61.3 ± 5.3 60.4 ± 6.2 0.61a
pGSN (mg/L) 123.1 ± 39.8 111.7 ± 27.0 129.5 ± 44.6 0.14a
pGSNN (10
−3) 2.05 ± 0.74 1.80 ± 0.45 2.19 ± 0.83 0.33a
72 hours after CPB (h)
TP (g/L) 64.4 ± 7.2 66.2 ± 7.7 63.1 ± 6.6 0.18a
pGSN (mg/L) 131.2 ± 39.6 124.6 ± 37.8 136.4 ± 41.3 0.33a
pGSNN (10
−3) 2.02 ± 0.63 1.92 ± 0.55 2.08 ± 0.67 0.31a
Data were expressed as the mean ± SD or median (interquartile range) if appropriated.
a: ANCOVA.
TP = plasma total protein amount; pGSN = plasma gelsolin; pGSNN = plasma gelsolin normalized by plasma total protein amount.
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the patients. Consistent with other age-match population,
the patients with CPB-ALI of this cohort did need longer
mechanical ventilation and ICU-stay time than patients
without ALI, which may related to addition lung fluid
retention, delayed recovery of ability of gas exchange
and lung mechanics, infectious or noninfectious pulmon-
ary complications, susceptibility to low cardiac output
syndrome and other institutional and practice guidelines
[25,26]. The prognosis of patients with CPB-ALI in thisstudy was good without hospital death and with similar
duration of hospital stay in both groups.
For the systemic inflammatory response was proposed
to play a pivotal role in the pathogenesis of CPB-induced
acute lung injury [27,28], various of factors concerned
inflammation, not only the changes in the levels, but also
the time courses or the patterns of release, had been de-
scribed for the affecting the incidence, severity and clinical
outcome of the CPB-ALI such as IL-6, IL-8, TNF-α and
endotoxins et al. Recent studies highlighting the novel
Figure 1 The time course of plasma gelsolin. A: Perioperative change of pGSN levels in ALI (green line) and non-ALI groups (blue line);
B: Perioperative change of pGSNN levels in ALI and non-ALI groups; *Two-way ANOVA, p < 0.05 versus before CPB (baseline level).
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surfactant derived protein B (SPB) and plasma receptor
for advanced glycation end products (RAGE), and have
shown to be a promising diagnostic method in both
adult and pediatric population [29,30]. Though, the change
of pGSN in acute lung injury was still controversial for the
differences of etiologies, study kinetic and damage severity.
As a novel inflammatory mediator, declining pGSN had
demonstrated its predictor and therapeutic value in several
acute lung injury model related to SIRS, such as sepsis,
burn and trauma [31-33]. In this study, we observed the
time course characteristics of pGSN of patients undergoing
open heart surgery with CPB, and its role in predicting the
occurrence and severity of CPB-ALI.Figure 2 The comparison of plasma gelsolin between two groups. A:
point; B: The comparison of pGSNN levels between two groups at each timThe total baseline level of pGSN (preoperative level) in
this study was (157.8 ± 52.8) mg/L, which was much
lower than of that of adult population of 190-300 mg/L
[34]. And the baseline level of pGSN of ALI patients was
significantly lower than that of patients without CPB-ALI
[(122.6 ± 24.6) mg/L vs. (176.4 ± 54.5) mg/L, p < 0.01].
This meant that patients with lower plasma gelsolin “res-
ervoir” were more prone to acute lung injury after CPB,
and lower preoperative pGSN level might be a possible
early predictor of CPB-ALI [15-18,35]. In addition, for
recombinant pGSN is available, gelsolin supplement could
be a safe and promising therapy in preventing and alle-
viating CPB-ALI before surgery in the future. We also
found that both pGSN and pGSNN of ALI group decreasedThe comparison of pGSN levels between two groups at each time
e point; *ANCOVA, p < 0.05.
Figure 4 The severity of CPB-ALI. PGSN before CPB was significantly negative correlated with the severity of CPB-ALI in this study (r=−0.45, p< 0.01).
Figure 3 ROC curve for pGSN before CPB. The AUC of pGSN before CPB for CPB-ALI was 0.753 (95%CI, 0.626 to 0.880).
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than those of non-ALI group (48 and 24 hours after CPB);
PGSN and pGSNN of ALI group at 6 hours after CPB were
much lower than those of non-ALI group. The depletion of
pGSN was due to the decreased production and increased
consumption. Though the production of gelsolin could not
be identified for the difference of individuals’ muscle mass,
we speculated a much more amount and rapid con-
sumption of plasma gelsolin in ALI group for two main
reasons. First, pGSN sequestration at lesions or clear-
ance with circulating actin released from damaged and
dying cells or tissues is a principal reason for depletion
of pGSN. Second, as an inflammatory mediator-binding
protein in the circulation, pGSN binds to the quantities of
inflammatory mediator and pro-inflammatory cytokines
provoked by CPB, as to alleviate the local and systemic
inflammatory response.
After collecting all the possible risk factors into final
multiple regression analysis, we found that pGSN before
CPB was the only independent risk factor predicting for
CPB-ALI (OR, 1.023; 95% CI, 1.007-1.039; p < 0.01), with
an AUC of 0.753 (95% CI, 0.626-0.880); The optimal
cutoff for pGSN before CPB was 264.2 mg/L, with a
sensitivity of 58.3% and a specificity 94.7%. And lower
pGSN before CPB was significantly associated with the
severity of CPB-ALI in this study (Figure 4, r = −0.45,
p < 0.01). These findings demonstrated that pGSN
before CPB could not only be a novel early biomarker
for CPB-ALI, but also a reliable quantitative factor
reflecting the severity of CPB-ALI in infants and young
children.
Limitation
Limitation of the present study should be acknowl-
edged. First, the study was based on a single medical
center, local practice patterns, and a small number of
patients, which might impede the application of present
findings to other institutions. Second, the population
of the study was restricted in the patients with CHD
below 3-year-old, so we could not be sure whether
these findings were available for elder children or adult
patients. Third, the gelsolin level in the lung tissue was
not detected in the study, therefore, the correlation of
gelsolin between site of injury and circulation was still
unclear.
Conclusions
Patients developing CPB-ALI had lower plasma gelsolin
reservoir and a much more amount and rapid consump-
tion of plasma gelsolin early after operation. PGSN before
CPB was an early and sensitive predictor of CPB-ALI in
infants and young children undergoing cardiac surgery
with CPB, and was negatively correlated with the severity
of CPB-ALI.Additional files
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